How androgens exert their anabolic effects.Interaction of testosterone and growth hormone at the hepatic level.

Phase 4

Recruiting

• Conditions: Metabolic and Endocrine - Diabetes; Men with hypogonadism; Men with hypopituitarism

• Registration Number: ACTRN12605000482662
• Lead Sponsor: Department of Endocrinology, St Vincents Hospital Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 36

Inclusion Criteria

Hypogonadism or hypopituitarism (baseline T < 2 nmol/L)

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biochemical markers of GH-IGF-axis and bone turnover[At baseline and after each 14 day treatment period];Measurements of substrate metabolism and protein turnover[At baseline and after each 14 day treatment period]

Secondary Outcome Measures

Name	Time	Method
one[]